Veppanu Prior Authorization Guideline
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
This guideline governs initial authorization and reauthorization of Veppanu 100 mg and 200 mg tablets. Coverage requires clinical eligibility, appropriate specialist prescribing, ESR1 mutation documentation, and prior treatment intolerance, failure, or contraindication as specified.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial authorization
Covered when all of the following criteria groups are met.
FDA-approved or NCCN-supported use
- FDA-approved use: Requested drug is FDA-approved for the condition being treated.
- NCCN-supported use: Treatment is supported for the diagnosis in the NCCN guidelines.
Specialist prescriber
- Hematologist: Prescribed by a hematologist.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.